Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905800 | 0.85 | CHRM3 (0.74) | CHRM3CHRM1CHRM2SLC6A2SLC6A4 | |
| SCHEMBL1009919 | 0.85 | CHRM3 (1.00) | CHRM3CHRM1CHRM2 | |
| SCHEMBL1009920 | 0.85 | CHRM3 (1.00) | CHRM3CHRM1CHRM2 | |
| SCHEMBL4914654 | 0.83 | CHRM3 (0.71) | CHRM3CHRM1CHRM2 | |
| SCHEMBL4905763 | 0.82 | CHRM3 (0.64) | CHRM3CHRM1CHRM2 | |
| SCHEMBL4168576 | 0.79 | CHRM3 (0.89) | CHRM3CHRM1CHRM2 | |
| SCHEMBL4168579 | 0.79 | CHRM3 (0.89) | CHRM3CHRM1CHRM2 | |
| SCHEMBL4254213 | 0.77 | CHRM3 (0.66) | CHRM3CHRM1CHRM2 | |
| SCHEMBL3816359 | 0.77 | CHRM3 (0.65) | CHRM3CHRM1CHRM2 | |
| SCHEMBL5099829 | 0.76 | CHRM3 (0.70) | CHRM3CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | GLAXO GROUP LIMITED | 2008-11-06 | — | — | US | disclosed |
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234315-A1 | M3 Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM1 3/4885CHRM2 2/4885 |
| US-20080275079-A1 | 3-Endo)-3-[2,2-Bis-(3-hydroxy-phenyl)-ethenyl]-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane bromide; chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, allergic rhinitis | CHRM3, EDNRB, BDKRB2 | CHRM3 1/4885CHRM1 27/4885CHRM2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.